New Years' Resolutions
This article was originally published in RPM Report
Executive Summary
If a panel of analysts are correct, the coming year will bring the reintroduction of Biogen-Idec's Tysabri, approval of Merck's human papilloma virus vaccine Gardasil and a continued stalemate over generic biologics. We asked top pharmaceutical analysts to weigh in on the events they think will move the market in 2006.
You may also be interested in...
Borderline Insanity? Drug Importation May Get New Life in 2007
After receding into political obscurity for several years, drug importation has come back into focus on Capitol Hill. The chances for legislation getting through Congress and past a presidential veto are a long shot, but Wall Street is worried.
Borderline Insanity? Drug Importation May Get New Life in 2007
After receding into political obscurity for several years, drug importation has come back into focus on Capitol Hill. The chances for legislation getting through Congress and past a presidential veto are a long shot, but Wall Street is worried.
Wall Street Looks Ahead: Market-Moving Events that Will Shape 2007
Wall Street analysts are confident that Congress will pass drug safety legislation this year, but in a poll conducted by The RPM Report, they didn't agree on much else. The panel was split most other questions-from whether Congress would remove the "non-interference" clause under Medicare Part D to whether FDA would approve another cox-2 inhibitor.